Arbutus Biopharma Corp (NASDAQ: ABUS) shares were trading higher Tuesday after the company reported continued positive data from an ongoing Phase 1a/1b clinical trial with AB-729.
The new data demonstrates that in chronic hepatitis B subjects, a single, subcutaneous 90mg injection of AB-729 resulted in a mean HBsAg reduction of 1.23 log10 IU/mL at week 12.
Arbutus Biopharma is a biopharmaceutical company focused on hepatitis B. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing of lipid nanoparticle technology.
Arbutus shares were trading up 13.02% at $2.96 at the time of publication Tuesday. The stock has a 52-week high of $9.02 and a 52-week low of 82 cents.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
"Trading" - Google News
September 15, 2020 at 10:12PM
https://ift.tt/3koogcT
Why Arbutus Stock Is Trading Higher Today - Benzinga
"Trading" - Google News
https://ift.tt/2tBJjTS
https://ift.tt/3djUFhc
Bagikan Berita Ini
0 Response to "Why Arbutus Stock Is Trading Higher Today - Benzinga"
Post a Comment